Healthcare / Diagnostics & ResearchUpdated 2026-05-10 22:07 UTC

BME/CBAV stock hub

BME/CBAV has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BME/CBAVis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

893.8M

Madrid Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

BME/CBAV

In the news

Latest news · BME/CBAV

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E21.2

P25 n/aP50 n/aP75 n/a

ROE41

P25 n/aP50 n/aP75 n/a

ROIC34.7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BME/CBAV market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

241

Groups with data

Currency

EUR

Showing 241 of 241 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Spain
Country code	ES
Employees	1,910
Employees Change	151%
Employees Change Percent	8.58
Enterprise value	EUR 913.6M
Exchange	Madrid Stock Exchange
Financial currency	EUR
First seen	2026-05-10
Industry	Diagnostics & Research
Isin	ES0119037010
Last refreshed	2026-05-10
Market cap	EUR 893.8M
Price	EUR 55.8
Price currency	EUR
Rev Per Employee	191,525.16x
Sector	Healthcare
Sic	8000
Symbol	bme/CBAV
Website	https://www.clinicabaviera.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.71%
EV Earnings	21.72x
EV/EBIT	15.06x
EV/EBITDA	11.03x
EV/FCF	19.51x
EV/Sales	3x
FCF yield	5.24%
P/B ratio	8.06x
P/E ratio	21.24x
P/S ratio	2.93x
PE Ratio10 Y	14.69x
PE Ratio3 Y	13.27x
PE Ratio5 Y	12.29x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	19.89%
EBITDA Margin	27.15%
FCF margin	15.36%
Gross margin	49.52%
Gross Profit	EUR 151M
Gross Profit Growth	13.91%
Gross Profit Growth Q	15.36%
Gross Profit Growth3 Y	14%
Gross Profit Growth5 Y	20.92%
Net Income	EUR 42.1M
Net Income Growth	4.62%
Net Income Growth Q	12.98%
Net Income Growth Quarters	2%
Net Income Growth Years	11%
Net Income Growth3 Y	12.53%
Net Income Growth5 Y	24.71%
Pretax Margin	19.71%
Profit Margin	13.8%
Profit Per Employee	EUR 26,421
Profitable Years	13
ROA	16.48
Roa5y	18.23
ROCE	32.59
ROE	41.02
Roe5y	46.87
ROIC	34.66
Roic5y	39.32

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	30.3%
Cagr15y	17.26%
Cagr1y	52.98%
Cagr3y	48.59%
Cagr5y	40.01%
Div CAGR10	20.69%
Div CAGR3	6.49%
Div CAGR5	23.25%
EPS Growth	4.54
EPS Growth Q	12.8
EPS Growth Quarters	2
EPS Growth Years	11
EPS Growth3 Y	13.2
EPS Growth5 Y	25.16
FCF Growth	30.08%
FCF Growth Q	6.12%
FCF Growth3 Y	5.97%
FCF Growth5 Y	14.65%
OCF Growth	22.93%
OCF Growth Q	30.9%
OCF Growth10 Y	21.64%
OCF Growth3 Y	12.91%
OCF Growth5 Y	19.56%
Revenue Growth	14.75x
Revenue Growth Q	10.62x
Revenue Growth Quarters	22x
Revenue Growth Years	5x
Revenue Growth3 Y	15.39x
Revenue Growth5 Y	19.98x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 1.33
Assets	EUR 247.5M
Cash	EUR 50.3M
Current Assets	EUR 59.3M
Current Liabilities	EUR 61.5M
Debt	EUR 69.2M
Debt EBITDA	EUR 0.84
Debt Equity	EUR 0.62
Debt FCF	EUR 1.48
Equity	EUR 111M
Interest Coverage	26.58
Liabilities	EUR 136.6M
Long Term Assets	EUR 188.2M
Long Term Liabilities	EUR 75.1M
Net Cash	EUR -18.8M
Net Cash By Market Cap	EUR -2.11
Net Debt EBITDA	EUR 0.23
Net Debt Equity	EUR 0.17
Net Debt FCF	EUR 0.4
Tangible Book Value	EUR 69.9M
Tangible Book Value Per Share	EUR 4.36
WACC	8.06

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.97
Inventory Turnover	46.59
Net Working Capital	EUR -39.3M
Quick ratio	0.9
Working Capital	EUR -2.1M
Working Capital Turnover	EUR -126

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.08%
Dividend Growth	0%
Dividend Growth Years	0%
Dividend per share	EUR 1.57
Dividend Years	6
Dividend Yield	2.81%
Ex Div Date	2026-06-10
Last Dividend	EUR 1.27
Payout Frequency	Annual
Payout Ratio	59.75%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	1,309.78%
1Y total return	52.94%
200-day SMA	47.28
3Y total return	228.14%
50-day SMA	51.32
50-day SMA vs 200-day SMA	50over200
5Y total return	437.95%
All Time High	58
All Time High Change	-3.79%
All Time High Date	2026-05-08
All Time Low	2.51
All Time Low Change	2,127.54%
All Time Low Date	2013-01-04
ATR	1.7
Beta	0.77
Beta1y	0.49
Beta2y	0.58
Ch YTD	12.27
High	58
High52	58
High52 Date	2026-05-08
High52ch	-3.79%
Low	55.8
Low52	36.9
Low52 Date	2025-05-14
Low52ch	51.22%
Ma50ch	8.74%
Price vs 200-day SMA	18.01%
RSI	67.32
RSI Monthly	73.15
RSI Weekly	66.38
Sharpe ratio	1.39x
Sortino ratio	2.44
Total Return	2.74%
Tr YTD	12.27
Tr15y	989.79%
Tr1m	16.49%
Tr1w	-0.36%
Tr3m	0.36%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 60.6M
Operating Income Growth	8.97
Operating Income Growth Q	7.52
Operating Income Growth3 Y	13.06
Operating Income Growth5 Y	25.05
Operating margin	19.89

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,186,226%
Net Borrowing	-9,855,016
Shares Insiders	1.79%
Shares Institutions	6.97%
Shares Out	16,018,514
Shares Qo Q	0.04%
Shares Yo Y	0.08%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 46.8M
Average Volume	3,443.05x
Bv Per Share	6.87
CAPEX	EUR -30M
Ch10y	916.4
Ch15y	584.7
Ch1m	16.49
Ch1w	-0.36
Ch1y	48.4
Ch3m	0.36
Ch3y	195.2
Ch5y	342.9
Ch6m	36.77
Change	-1.41%
Change From Open	-3.79
Close	56.6
Days Gap	2.47
Depreciation Amortization	22,132,385
Dollar Volume	168,013.8
Earnings Date	2026-05-26
EBIT	EUR 60.6M
EBITDA	EUR 82.8M
EPS	EUR 2.63
F Score	5
FCF	EUR 46.8M
FCF EV Yield	5.13x
FCF Per Share	EUR 2.92
Financing CF	-36,454,262
Fiscal Year End	December
Founded	1,992
Goodwill	29,007,779
Graham Number	20.14422
Graham Upside	-63.9
Income Tax	EUR 17.2M
Investing CF	-45,016,537
Is Primary Listing	1
Last Earnings Date	2026-02-26
Last Report Date	2025-12-31
Lynch Fair Value	EUR 64.92
Lynch Upside	16.34
Ma150	48.35
Ma150ch	15.42%
Ma20	53.62
Ma20ch	4.08%
Net CF	-4,550,666
Next Earnings Date	2026-05-26
Open	58
P FCF Ratio	19.09
P OCF Ratio	11.63
Payment Date	2026-06-12
Position In Range	0
Ppne	143,140,220
Price Date	2026-05-08
Price EBITDA	EUR 10.8
Ptbv Ratio	12.79
Relative Volume	0.88x
Revenue	304,908,056x
Tax By Revenue	5.63x
Tax Rate	28.57%
Tr6m	36.77%
Volume	3,011
Z Score	5.09

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

BME/CBAV dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+2.8%

$1.57 annual per share

Payout ratio

+59.7%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+23.3%

0 consecutive years of growth

Total shareholder yield

+2.7%

Next ex-dividend date: 2026-06-10

Performance

BME/CBAV stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BME/CBAV?

Insider, institutional, and short-interest positioning.

Institutional ownership

+7.0%

Share of float held by funds and institutions

Insider ownership

+1.8%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.1%

Negative means the company is buying back shares.

Technical

BME/CBAV momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

67.3

Neutral momentum band

Price vs 200-day MA

+18.0%

50/200-day relationship not available

Beta (5Y)

0.77

Less volatile than the market

Sharpe ratio

1.39

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BME/CBAV

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bme/CBAV stock rating?

bme/CBAV is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bme/CBAV analysis?

The full report lives at /stocks/bme/CBAV/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bme/CBAV?

The latest report frames bme/CBAV around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bme/CBAV page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.